logo
Book a meeting
IconOVir Bio

Icon O Vir Bio

Biotechnology, 4570 Executive Dr Ste 350, San Diego, California, 92121, United States, 11-50 Employees

iconovir.com

  • LinkedIn

Who is ICONOVIR BIO

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncol...

Read More

lock icon Get Full Access
map
  • 4570 Executive Dr Ste 350, San Diego, California, 92121, United States Headquarters: 4570 Executive Dr Ste 350, San Diego, California, 92121, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ICONOVIR BIO

IconOVir Bio Org Chart and Mapping

Employees
John Huynh

John Huynh

Chief Technology Officer

Pavla Hook

Pavla Hook

Senior Executive Assistant

Heba Nowyhed

Heba Nowyhed

Chief Scientific Officer

Julie Maltzman

Julie Maltzman

Chief Medical Officer

See Full Org Chart arrow
email-formate-icon
View Email Formats for IconOVir Bio
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding IconOVir Bio

Answer: IconOVir Bio's headquarters are located at 4570 Executive Dr Ste 350, San Diego, California, 92121, United States

Answer: IconOVir Bio's official website is https://iconovir.com

Answer: IconOVir Bio's revenue is $1 Million to $5 Million

Answer: IconOVir Bio's SIC: 2836

Answer: IconOVir Bio's NAICS: 541714

Answer: IconOVir Bio has 11-50 employees

Answer: IconOVir Bio is in Biotechnology

Answer: IconOVir Bio contact info: Phone number: Website: https://iconovir.com

Answer: IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh OShea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access